Date & Time: Thursday, September 28 at 4:00pm

Location: Oak Grove Auditorium – Forsyth Tech Main Campus, 2100 Silas Creek Parkway, 27103

Featured Speaker: Aaron Lazarus, CEO, EncepHeal Therapeutics

More than 24 million Americans suffer from addiction and substance use disorders, of whom only 11% actively seek treatment (SAMHSA, 2014). To make matters worse, there is both a scarcity of and limited success with Food and Drug Administration (FDA)-approved pharmaceuticals for the treatment of substance use disorders in this $35 billion dollar industry. There are no approved treatments for psychostimulant addictions (cocaine, meth, adderall, etc.).

Recently, the NIH and other academic institutions have developed new and innovative approaches to developing potential treatments for psychostimulant addictions. However, due to the untested market for substance abuse and the developmental shift of the pharmaceutical industry as a whole, pharmaceutical companies are reluctant to assess them at the laboratory discovery stage, thus creating a development gap between promising research and the later stage trials necessary for commercialization.

So, we created EncepHeal Therapeutics to bridge this gap and propel innovative biomedical discoveries into next generation neurotherapeutics. We will start with a first in class treatment of chemically modified modafinil analogs to treat psychostimulants.

To reserve a seat at this event, contact Mary Flournoy at 336-757-3812 or Russ Read at 336-734-7651.